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Association between elevated C-reactive protein (CRP) serum levels and subclinical atherosclerosis 
and cardiovascular (CV) events was described in rheumatoid arthritis (RA). CRP, HNF1A, LEPR, GCKR, 
NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 exert an influence on elevated CRP serum levels 
in non-rheumatic Caucasians. Consequently, we evaluated the potential role of these genes in the 
development of CV events and subclinical atherosclerosis in RA patients. Three tag CRP polymorphisms 
and HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 were genotyped 
in 2,313 Spanish patients by TaqMan. Subclinical atherosclerosis was determined in 1,298 of them 
by carotid ultrasonography (by assessment of carotid intima-media thickness-cIMT-and presence/
absence of carotid plaques). CRP serum levels at diagnosis and at the time of carotid ultrasonography 
were measured in 1,662 and 1,193 patients, respectively, by immunoturbidimetry. Interestingly, 
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a relationship between CRP and CRP serum levels at diagnosis and at the time of the carotid 
ultrasonography was disclosed. However, no statistically significant differences were found when CRP, 
HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 were evaluated according 
to the presence/absence of CV events, carotid plaques and cIMT after adjustment. Our results do not 
confirm an association between these genes and CV disease in RA.
Rheumatoid arthritis (RA) is a chronic disease related to an increased risk of cardiovascular (CV) mortality and 
high prevalence of subclinical atherosclerosis1. Besides traditional CV risk factors2 and inflammation3, a genetic 
component appears to be crucial in these processes2,4–6.
C-reactive protein (CRP) is currently the most widely used biomarker of inflammation7. The production of 
this protein occurs almost exclusively in the liver8. Several studies have suggested that elevated serum concentra-
tions of CRP are related to the development of several processes associated with atherosclerosis such as coronary 
heart disease9 and stroke10. Accordingly, a relationship between chronic inflammation determined by CRP serum 
levels and the development of both subclinical atherosclerosis11 and CV events2 has been found in RA patients.
Genetic variation is a major determinant of CRP levels. In this sense, a meta-analysis has identified several 
loci associated with elevated CRP serum levels in non-rheumatic Caucasian individuals12. CRP gene was found 
to be the most significant signal related to increased CRP serum levels12. Other polymorphisms also exert an 
influence on the elevated level of serum CRP in non-rheumatic Caucasians12. It is the case for common genetic 
variants that play a role in the immune system (NLRP3 [NACHT, LRR and PYD domains-containing protein 3] 
rs12239046 or IL1F10 [interleukin-1 family, member 10] rs6734238) or in the susceptibility to develop metabolic 
syndrome (HNF1A [hepatic nuclear factor 1-α] rs1183910, LEPR [leptin receptor] rs4420065, GCKR [glucokinase 
regulator] rs1260326 and HNF4A [hepatocyte nuclear factor 4-α] rs1800961)12. A relationship between genetic 
variants that reside in regions without an apparent role in chronic inflammation (PPP1R3B [protein phosphatase 
1, regulatory-inhibitor- subunit 3B] rs9987289, SALL1 [sal-like 1] rs10521222 and ASCL1 [achaete-scute com-
plex homolog 1] rs10745954) and increased CRP serum levels was also disclosed in non-rheumatic Caucasian 
individuals12.
Taking together all this information, the aim of the present study was to evaluate the potential influence of 
CRP, HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1, polymorphisms related to 
elevated CRP serum levels in non-rheumatic Caucasians, on the development of CV events and subclinical ather-
osclerosis in RA patients. For this purpose, we took advantage of data from a large series of RA patients assessed 
for CV disease.
Patients and Methodology
Subjects and Study Protocol. 2,313 unrelated patients from Spain were enrolled in our work. Peripheral 
blood was obtained from subjects recruited from Hospital Universitario Lucus Augusti (Lugo), Marqués de 
Valdecilla (Santander), Bellvitge (Barcelona), San Cecilio (Granada), Canarias (Tenerife), Doctor Peset (Valencia), 
General de Ciudad Real (Ciudad Real) and Clínico San Carlos, La Paz, La Princesa, Gregorio Marañón and 12 de 
Octubre (Madrid).
For experiments involving humans and the use of human blood samples, all the methods were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. All exper-
imental protocols were approved by the Ethics Committees of clinical research of Galicia for Hospital Lucus 
Augusti in Lugo, of Cantabria for Hospital Marqués de Valdecilla in Santander, of Cataluña for Hospital de 
Bellvitge in Barcelona, of Andalucía for Hospital San Cecilio in Granada, of Canarias for Hospital de Canarias 
in Tenerife, of Comunidad Valenciana for Hospital Doctor Peset in Valencia, of Castilla-La Mancha for Hospital 
General de Ciudad Real in Ciudad Real and of Madrid for Hospital Clínico San Carlos, La Paz, La Princesa, 
Gregorio Marañón and 12 de Octubre in Madrid. Informed consent was obtained from all subjects.
Patients fulfilled the 2010 classification criteria for RA13. RA patients were evaluated for CRP, HNF1A, LEPR, 
GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 polymorphisms. In addition, subclinical athero-
sclerosis was determined in 1,298 of the RA patients recruited in the study using a carotid ultrasound (US) tech-
nique (by evaluation of carotid intima-media thickness -cIMT- and presence/absence of carotid plaques). Also, 
CRP serum levels at the time of RA diagnosis and at the time of carotid US study were measured in a subgroup of 
1,662 and 1,193 patients, respectively, by immunoturbidimetry.
Data on epidemiological and demographical features of the patients recruited in the present work are dis-
played in Table 1. Traditional CV risk factors and CV events were defined previously2,14.
Selection of polymorphisms and genotyping. Since CRP has been identified as the most relevant signal 
related to elevated CRP serum levels in non-rheumatic Caucasians12, we performed a tagging of this gene with the 
aim of covering all its variability. Consequently, we genotyped 3 polymorphisms: CRP rs1417938, CRP rs1800947 
and CRP rs1205.
Additionally, we tested 9 genetic variants (HNF1A rs1183910, LEPR rs4420065, GCKR rs1260326, NLRP3 
rs12239046, IL1F10 rs6734238, PPP1R3B rs9987289, ASCL1 rs10745954, HNF4A rs1800961 and SALL1 
rs10521222) previously described as relevant polymorphisms related to increased CRP serum levels in 
non-rheumatic Caucasians12.
Genotyping was performed by TaqMan predesigned assays in a 7900 HT Real-Time polymerase chain reac-
tion system (Applied Biosystems, Foster City, CA, USA).
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US evaluation. Measurement of the cIMT values and presence/absence of carotid plaques were evaluated 
in 1,298 cases. Patients from Santander, Granada, Tenerife, Valencia, Ciudad Real and Madrid were evaluated 
by a commercially scanner, Mylab 70, Esaote (Genoa-Italy) as previously described15. Patients from Lugo were 
measured by high-resolution B-mode ultrasound, Hewlett Packard SONOS 5500 as previously reported16. cIMT 
was measured at the far wall of the right and left common carotid arteries over the proximal 15 mm-long segment. 
cIMT was determined as the average of three measurements in each common carotid artery. Plaque criteria in the 
accessible extracranial carotid tree (common carotid artery, bulb and internal carotid artery) were focal protru-
sion in the lumen at least cIMT > 1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial 
lumen encroaching > 0.5 mm17. The carotid plaques were counted in each territory and defined as no plaque, 
unilateral plaque or bilateral plaques17. Agreement between these two US methods was previously reported18. 
Experts with a high reproducibility and an excellent inter-observer reliability in the evaluation of subclinical 
atherosclerosis in patients with RA performed the studies.
Evaluation of CRP serum levels. CRP serum levels at the time of RA diagnosis and at the time of the 
carotid US study were measured in a subgroup of 1,662 and 1,193 patients, respectively, by an automated immu-
noturbidimetric assay using the ADVIA Chemistry system (Siemens Healthcare Diagnostics Inc.). Serum sam-
ples of RA patients containing CRP form an immune complex with the assay reagent and antibodies against CRP 
that precipitates, increasing the turbidity of the sample. When light is passed through the reaction solution, some 
light is absorbed by the precipitates, which is measured at 596/694 nm. The level of CRP is determined by com-
parison with a calibrator of known concentration.
Statistical analysis. Genotyping data were checked for deviation from Hardy-Weinberg equilibrium 
(HWE) using http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. Power for the study was calculated using “CaTS-Power 
Calculator for Two Stage Association Studies” (http://www.sph.umich.edu/csg/abecasis/CaTS/). Haplotypes were 
constructed using Haploview v4.2 software.
The relationship between allele/haplotype frequencies and the presence/absence of CV events was tested using 
Cox regression adjusting for gender, follow-up time, age at RA diagnosis and traditional CV risk factors as con-
founder factors. Results were expressed as hazard ratios (HR) with 95% confidence interval (CI).
Differences in the allele/haplotype frequencies according to the presence/absence of carotid plaques were 
calculated by χ 2 or Fisher tests when necessary (expected values below 5). Strength of associations was estimated 
using odds ratios (OR) and 95% CI. Results were adjusted for gender, follow-up time, age at the time of US eval-
uation and traditional CV risk factors as confounder factors by logistic regression.
Association between allele/haplotype frequencies and data on cIMT was evaluated by unpaired t test. Results 
were adjusted for gender, follow-up time, age at the time of US evaluation and traditional CV risk factors as con-
founder factors by analysis of covariance (ANCOVA).
Results on CRP serum levels were expressed as mean ± standard deviation (SD). The relationship between 
allele/haplotype frequencies and CRP serum levels at RA diagnosis and at the time of the carotid US study was 
evaluated by unpaired t test.
Variables % (n/N)
Age at RA onset (years, mean ± SD) 51.0 ± 14.7
Follow-up time (years, mean ± SD) 11.6 ± 8.7
Women (%) 72.4
RF positive* 64.8 (1,265/1,952)
Anti-cyclic citrullinated peptide antibodies 
positive 58.7 (1,171/1,996)
Erosions 55.6 (1,086/1,954)
Extra-articular manifestations** 25.0 (448/1,789)
Cardiovascular risk factors 
Hypertension 37.6 (822/2,185)
Diabetes mellitus 12.1 (264/2,185)
Dyslipidemia 36.4 (796/2,185)
Obesity 21.7 (474/2,185)
Smoking habit 35.3 (772/2,185)
Cardiovascular events 16.7 (386/2,313)
Ischemic heart disease 7.8 (181/2,313)
Heart failure 5.7 (131/2,313)
Cerebrovascular accident 4.7 (108/2,313)
Peripheral arteriopathy 2.1 (49/2,313)
Table 1.  Data on epidemiological and demographical features of the 2,313 patients with rheumatoid 
arthritis from Spain recruited in this work. SD: Standard deviation; RF: rheumatoid factor. *At least two 
determinations were required. **As previously described2.
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The statistical software used to perform all the statistical analyses was STATA 12/SE (Stata Corp., College 
Station, TX, USA).
Results
CRP rs1417938, CRP rs1800947, CRP rs1205, HNF1A rs1183910, LEPR rs4420065, GCKR rs1260326, NLRP3 
rs12239046, IL1F10 rs6734238, PPP1R3B rs9987289, ASCL1 rs10745954, HNF4A rs1800961 and SALL1 
rs10521222 genotype distribution were in HWE (p > 0.05). The genotyping success was greater than 99% in all 
the cases.
The study had > 90% of power to detect genotypic OR = 1.3 for CRP rs1417938, CRP rs1205 and HNF1A 
rs1183910, LEPR rs4420065, GCKR rs1260326, NLRP3 rs12239046, IL1F10 rs6734238, ASCL1 rs10745954, 
and ≥ 90% to detect OR ≥ 1.4 for CRP rs1800947 and PPP1R3B rs9987289 and HNF4A rs1800961 and SALL1 
rs10521222.
Influence of CRP polymorphisms on CV events or subclinical atherosclerosis in patients with RA. 
We assessed the potential influence of CRP polymorphisms (rs1417938, rs1800947 and rs1205) on the risk of CV 
events or subclinical atherosclerosis in RA patients.
The linkage disequilibrium (LD) pattern of these 3 CRP polymorphisms obtained by HapMap Project phase I, 
II and III and Haploview (v.4.2) software and measured by r2 coefficient is displayed in Supplementary Fig. online.
After adjustment for potential confounder factors, no statistically significant differences were found when 
each CRP polymorphism was assessed independently and according to the presence/absence of CV events, 
carotid plaques and cIMT values (Table 2). Similarly, after adjustment for potential confounder factors, no statisti-
cally significant differences were detected when CRP polymorphisms were tested together conforming haplotypes 
and according to the presence/absence of CV events, carotid plaques and cIMT values (Table 3).
Influence of HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 pol-
ymorphisms on CV events or subclinical atherosclerosis in patients with RA. In addition, we 
evaluated the potential relationship between HNF1A rs1183910, LEPR rs4420065, GCKR rs1260326, NLRP3 
rs12239046, IL1F10 rs6734238, PPP1R3B rs9987289, ASCL1 rs10745954, HNF4A rs1800961 and SALL1 
rs10521222 polymorphisms and CV events or subclinical atherosclerosis in RA patients (Table 4). Accordingly, 
no significant differences were obtained when RA patients were stratified according to the presence/absence of 
CV events after adjustment for potential confounder factors (Table 4). It was also the case when RA patients were 
stratified according to the presence/absence of carotid plaques and the evaluation of cIMT after adjustment for 
potential confounder factors (Table 4).
Change
Presence/absence of CV 
events (n = 2,313)
Presence/absence of carotid 
plaques (n = 1,298) cIMT (n = 1,298)
P* HR [95% CI]* P** OR [95% CI]** P***
CRP rs1417938 T/A 0.26 1.18 [0.88–1.58] 0.24 0.87 [0.69–1.10] 0.63
CRP rs1800947 C/G 0.57 0.83 [0.43–1.58] 0.78 1.07 [0.66–1.75] 0.39
CRP rs1205 C/T 0.72 1.06 [0.78–1.43] 0.35 1.12 [0.88–1.42] 0.35
Table 2.  Association between CRP polymorphisms according to the presence/absence of CV events or 
subclinical atherosclerosis in RA patients. CV: cardiovascular; RA: rheumatoid arthritis; cIMT: carotid 
intima-media thickness; HR: hazard ratios; CI: confidence interval; OR: odds ratio. *Adjustment for gender, 
follow-up time, age at RA diagnosis and traditional CV risk factors by Cox regression. **Adjustment for gender, 
follow-up time, age at the time of ultrasonography study and traditional CV risk factors by logistic regression. 
***Adjustment for gender, follow-up time, age at the time of ultrasonography study and traditional CV risk 
factors using analysis of covariance (ANCOVA).
Haplotypes Presence/absence of CV events
Presence/absence of 
carotid plaques cIMT
rs1417938 rs1800947 rs1205 P* HR [95% CI]* P** OR [95% CI]** P***
T C C — 1 (reference) — 1 (reference) —
A C C 0.21 1.19 [0.90–1.60] 0.21 1.14 [0.92–1.41] 0.54
T C T 0.37 0.86 [0.62–1.19] 0.78 0.95 [0.64–1.39] 0.41
A C T 0.72 0.93 [0.62–1.39] 0.60 1.15 [0.69–1.89] 0.60
Table 3.  Results of CRP haplotype analysis according to the presence/absence of CV events or subclinical 
atherosclerosis in RA patients. CV: cardiovascular; RA: rheumatoid arthritis; cIMT: carotid intima-media 
thickness; HR: hazard ratios; CI: confidence interval; OR: odds ratio. *Adjustment for gender, follow-up time, 
age at RA diagnosis and traditional CV risk factors by Cox regression. **Adjustment for gender, follow-up time, 
age at the time of ultrasonography study and traditional CV risk factors by logistic regression. ***Adjustment 
for gender, follow-up time, age at the time of ultrasonography study and traditional CV risk factors using 
analysis of covariance (ANCOVA).
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Influence of CRP, HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 
polymorphisms on CRP serum levels in patients with RA. Furthermore, we determined the poten-
tial influence of CRP, HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 on CRP 
serum levels at RA diagnosis and also at the time of the carotid US study. In this regard, the mean ± SD of CRP 
serum levels at RA diagnosis in patients carrying the minor CRP rs1417938A allele was 12.66 ± 25.32 mg/l versus 
9.80 ± 19.39 mg/l in those carrying the major CRP rs1417938T allele (p = 0.0002) (Supplementary Table S1). 
Additionally, the mean ± SD of CRP serum levels at the time of the carotid US study in patients carrying the 
minor CRP rs1417938A allele was 7.15 ± 19.16 mg/l versus 5.64 ± 14.56 mg/l in those carrying the major CRP 
rs1417938T allele (p = 0.029) (Supplementary Table S1). Moreover, the mean ± SD of CRP serum levels at 
the time of the carotid US study in patients carrying the minor CRP rs1205T allele was 5.02 ± 12.81 mg/l ver-
sus 6.71 ± 17.70 mg/l in those carrying the major CRP rs1205C allele (p = 0.018) (Supplementary Table S1). 
Consistent with these results, the mean ± SD of CRP serum levels at RA diagnosis in patients carrying the ACC 
haplotype (which harbors the minor CRP rs1417938A allele) was 14.08 ± 28.28 mg/l versus 10.23 ± 19.90 mg/l 
in those patients carrying the TCC haplotype, the most common haplotype found in our series (p = 0.0002) 
(Supplementary Table S2). Also, the mean ± SD of CRP serum levels at the time of the carotid US study in 
patients carrying the TCT haplotype (which harbors the minor CRP rs1205T allele) was 4.34 ± 7.75 mg/l versus 
6.14 ± 16.46 mg/l in those patients carrying the TCC haplotype (p = 0.023) (Supplementary Table S2). However, 
no association between HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 and both 
CRP serum levels at RA diagnosis and at the time of the carotid US study was disclosed (Supplementary Table S3).
Discussion
Several studies have suggested that CRP has direct effects on the vessel wall promoting atherosclerosis19. Among 
them, CRP seems to stimulate the production of cellular adhesion molecules by vascular endothelial cells, facili-
tate the adhesion and migration of monocytes through the vessel wall, mediate the uptake of low-density lipopro-
tein cholesterol by macrophages and cause complement activation19.
An association between high-grade, chronic CRP elevation and subclinical atherosclerosis in patients with 
RA has been reported11. Additionally, a higher risk of CV events in patients with RA with chronic inflammation 
expressed by persistently increased CRP serum levels has been found2.
Since CRP, HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 have been described 
as significant signals associated with elevated CRP serum levels in non-rheumatic Caucasians12, we set up a 
large-scale study to determine the potential influence of these 10 genetic variants on the development of ather-
osclerotic disease in patients with RA. Interestingly, our results disclosed a relationship between CRP gene and 
CRP serum levels at RA diagnosis and at the time of the carotid US study. However, we could not find an associ-
ation between the elevated CRP serum level-related variants in non-rheumatic Caucasians and the presence of 
subclinical atherosclerosis or CV events in RA patients.The lack of evidence for the association between these 
polymorphisms and atherosclerosis in RA patients does not exclude the implication of CRP in the pathogenesis 
of this disease. This protein is produced as a part of an intricate acute phase response where several inflammatory 
Change
Presence/absence 
of CV events 
(n = 2,313)
Presence/absence 
of carotid plaques 
(n = 1,298)
cIMT 
(n = 1,298)
P*
HR  
[95% CI]* P**
OR  
[95% CI]** P***
HNF1A rs1183910 G/A 0.96 0.99 [0.73–1.36] 0.55
0.93 
[0.73–1.18] 0.63
LEPR rs4420065 C/T 0.24 1.19 [0.89–1.58] 0.57
0.94 
[0.75–1.18] 0.54
GCKR rs1260326 C/T 0.51 0.91 [0.68–1.21] 0.36
1.11 
[0.89–1.38] 0.35
NLRP3 rs12239046 C/T 0.72 0.95 [0.71–1.27] 0.19
0.86 
[0.69–1.08] 0.57
IL1F10 rs6734238 A/G 0.88 0.98 [0.74–1.30] 0.17
1.17 
[0.94–1.46] 0.34
PPP1R3B rs9987289 G/A 0.55 0.84 [0.46–1.52] 0.60
0.89 
[0.59–1.36] 0.19
ASCL1 rs10745954 A/G 0.81 1.04 [0.78–1.38] 0.67
0.95 
[0.76–1.19] 0.92
HNF4A rs1800961 C/T 0.32 1.51 [0.67–3.43] 0.50
1.27 
[0.63–2.60] 0.72
SALL1 rs10521222 C/T 0.97 1.01 [0.53–1.91] 0.58
0.87 
[0.53–1.43] 0.75
Table 4.  Association between HNF1A, LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A, 
SALL1 according to the presence/absence of CV events or subclinical atherosclerosis in RA patients. 
CV: cardiovascular; RA: rheumatoid arthritis; cIMT: carotid intima-media thickness; HR: hazard ratios; CI: 
confidence interval; OR: odds ratio. *Adjustment for gender, follow-up time, age at RA diagnosis and traditional 
CV risk factors by Cox regression. **Adjustment for gender, follow-up time, age at the time of ultrasonography 
study and traditional CV risk factors by logistic regression. ***Adjustment for gender, follow-up time, age at the 
time of ultrasonography study and traditional CV risk factors using analysis of covariance (ANCOVA).
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factors, closely interrelated, are involved. Although we could not find an association of IL6 gene polymorphisms 
with CV disease20, it is possible that complex interactions between elevated CRP serum level-related genes in 
non-rheumatic Caucasians and other genes implicated in the inflammation cascade may lead to up-regulation of 
CRP, promoting the progression of accelerated atherosclerosis in RA patients.
In summary, the results obtained in the present study do not confirm association between CRP, HNF1A, 
LEPR, GCKR, NLRP3, IL1F10, PPP1R3B, ASCL1, HNF4A and SALL1 and CV disease in patients with RA.
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